Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors Pol Boudes, MD, brings extensive medical research and development experience in Fabry disease, orphan drugs and medica

Protalix BioTherapeutics Adds Two Accomplished

Biopharmaceutical Executives to its Board of Directors

Pol Boudes, MD, brings extensive medical

research and development experience in Fabry disease, orphan drugs and medical innovation

Gwen Melincoff brings extensive experience

in biotechnology and pharmaceutical business development, deal-formation and venture capital funding

CARMIEL, Israel, December 19,

2019 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused

on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary

ProCellEx plant cell-based protein expression system, today announced the appointment of Pol F. Boudes, MD,

and Gwen A. Melincoff to its Board of Directors, effective as of January 1, 2020. The new appointments will expand the size

of the Board from five to seven directors.

Pol Boudes, MD, a senior physician,

brings more than 25 years of experience in medical research and development, with a special emphasis on orphan drugs and translational

medicine. Dr. Boudes currently serves as a research and development consultant to several companies. Most recently he served as

Chief Medical Officer at CymaBay Therapeutics, Inc. He was also previously Chief Medical Officer at Amicus Therapeutics, Inc.,

where he directed the development of the migalastat treatment for Fabry disease.

Gwen Melincoff brings more than 25

years of business development and venture capital leadership experience in the biotechnology and pharmaceutical industries. Ms.

Melincoff currently serves on the Board of Directors of Collegium Pharmaceutical, Inc., Soleno Therapeutics, Inc. and Photocure

"We are delighted to welcome

Pol and Gwen, both of whom have definitional experience in building and leading successful commercial organizations," said

Zeev Bronfeld, Protalix's Chairman of the Board. "Each is a world-class leader in their fields and together they bring

excellent and differentiated skills that will be vital in guiding Protalix forward."

"We look forward to Pol's

and Gwen's valuable insights and contributions to our Board," said Dror Bashan, Protalix's President and Chief

Executive Officer. "They each have a record of success in the development of therapeutics globally and we look forward to

benefiting from their guidance as we continue to advance our clinical pipeline towards commercialization."

Dr. Boudes currently serves as a research and development consultant

to several research and development organizations. From April 2014 through October 2019, he served as the Chief Medical Officer

of CymaBay Therapeutics where he led the development of CymaBay Therapeutics' treatments for rare liver diseases. Dr. Boudes

was also Chief Medical Officer at Amicus Therapeutics from 2009 to 2013 where he was instrumental in the development of migalastat

(Galafold ) for the treatment of Fabry disease, as well as treatments for Pompe disease and Gaucher disease.

Dr. Boudes has also served as the Chief

Medical Officer for three orphan drug/rare disease companies: Alkeus Pharmaceuticals, Antidote Therapeutic Inc., and BioAegis Therapeutics.

He has served in various roles at Berlex Laboratories (acquired by Bayer HealthCare Pharmaceuticals), Wyeth-Ayerst Research, Hoffmann-La

Roche and Pasteur-Merieux Serums & Vaccines. Dr. Boudes holds an M.D. from the University of Aix-Marseilles, France, and has

specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases.

Gwen Melincoff previously served as

Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company. Prior to BTG, Ms. Melincoff

was Senior Vice President of Corporate Development at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the

venture capital arm of Shire Plc. Ms. Melincoff was Vice President of Business Development at Adolor Corporation and held executive

positions at Eastman Kodak for over ten years in a number of their health care companies.

Ms. Melincoff holds a B.S. in Biology

from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University,

and has completed graduate studies in Physiology at Jefferson Medical College. Ms. Melincoff has also attained the designation

of Certified Licensing Professional (CLP ). Ms. Melincoff was named to the "Top Women in Biotech 2013" by Fierce

Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.

About Protalix BioTherapeutics,

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed

through its proprietary plant cell-based expression system, ProCellEx . Protalix was the first company to gain U.S. Food and

Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's

unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix's

first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently,

by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization

rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline consists

of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical

markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A

protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the

treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and

outside the United States, for the development and commercialization of pegunigalsidase alfa.

Forward-Looking Statements

To the extent that statements in this

press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions

of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe,"

"estimate," "project," "plan," "should" and "intend," and other words

or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject

to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the

statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery

and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings

for the clinical trial. Factors that might cause material differences include, but are not limited to: capital market risks; our

ability to raise additional capital when needed; and other risk factors identified in Part I, Item 1A "Risk Factors,"

of our Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Reports on Form 10-Q for the

periods ended June 30, 2019 and September 30, 2019, as filed with the U.S. Securities and Exchange Commission (SEC)

and in other reports we file from time to time with the SEC, including our Quarterly Reports on Form 10-Q and Current Reports

on Form 8-K, which are all available at www.sec.gov and on our website. The statements in this press release are valid only

as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.

Chuck Padala, Managing Director